Next Article in Journal
Hope for GWAS: Relevant Risk Genes Uncovered from GWAS Statistical Noise
Next Article in Special Issue
Lung Injury Induced by TiO2 Nanoparticles Depends on Their Structural Features: Size, Shape, Crystal Phases, and Surface Coating
Previous Article in Journal
Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
Previous Article in Special Issue
Effect of Fiber Length on Carbon Nanotube-Induced Fibrogenesis
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2014, 15(10), 17577-17600;

Right or Left: The Role of Nanoparticles in Pulmonary Diseases

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing 100190, China
Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei 230027, Anhui, China
Author to whom correspondence should be addressed.
Received: 21 February 2014 / Revised: 25 August 2014 / Accepted: 25 August 2014 / Published: 29 September 2014
(This article belongs to the Special Issue Nanotoxicology and Lung Diseases)
Full-Text   |   PDF [3462 KB, uploaded 29 September 2014]   |  


Due to the rapid development of the nanotechnology industry in the last decade, nanoparticles (NPs) are omnipresent in our everyday life today. Many nanomaterials have been engineered for medical purposes. These purposes include therapy for pulmonary diseases. On other hand, people are endeavoring to develop nanomaterials for improvement or replacement of traditional therapies. On the other hand, nanoparticles, as foreign material in human bodies, are reported to have potential adverse effects on the lung, including oxidase stress, inflammation, fibrosis and genotoxicity. Further, these damages could induce pulmonary diseases and even injuries in other tissues. It seems that nanoparticles may exert two-sided effects. Toxic effects of nanomaterials should be considered when their use is developed for therapies. Hence this review will attempt to summarize the two-side roles of nanoparticles in both therapies for pulmonary diseases and initiation of lung diseases and even secondary diseases caused by lung injuries. Determinants of these effects such as physicochemical properties of nanoparticles will also be discussed. View Full-Text
Keywords: nanoparticle; pulmonary pathobiological processes; lung disease; therapy nanoparticle; pulmonary pathobiological processes; lung disease; therapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lu, X.; Zhu, T.; Chen, C.; Liu, Y. Right or Left: The Role of Nanoparticles in Pulmonary Diseases. Int. J. Mol. Sci. 2014, 15, 17577-17600.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top